Incyte公司的培美替尼说明书

Incyte Company Instructions

Generic name: pemigatinib

Product name: pemazyre

Full names: pemetinib, pemetinib, pemigatinib, pemazyre

Indications:

Pemetinib is indicated for cholangiocarcinoma that has metastasized (spread to other parts of the body) or is locally advanced and cannot be treated with surgery. Pemetinib is used to treat adults with FGFR2 gene fusions or other changes in the structure of the FGFR2 gene.

How to take:

The recommended dose of pemetinib is 13.5 mg orally daily for 14 days, followed by 7 days off in a 21-day cycle. Continue treatment until disease progression or unacceptable toxicity. Pemetinib is swallowed whole, with or without food.

Side effects:

Pemetinib side effects include: diarrhea, nausea, weight loss, constipation, stomach pain, change in taste, vomiting, loss of appetite, mouth sores, dry mouth and/or dry skin; decreased urine output; or rapid heartbeat.

Pemetinib also has side effects: nail inflammation, headache, fatigue, joint pain, hair loss, painful urination, and swelling and pain in limbs or joints.

Pemetinib side effects include blurred vision, eye floaters, seeing flashes of light or other vision changes, muscle spasms, numbness, or dry mouth.

Things to note:

1. Pemetinib can cause retinal pigment epithelial detachment. Ophthalmological examinations, including optical coherence tomography (OCT), were performed before the start of treatment, every 2 months for the first 6 months of treatment and every 3 months thereafter, and at any time visual symptoms emerged urgently.

2. Hyperphosphatemia: Increased phosphate levels are the pharmacodynamic effect of pemetinib. Monitor and prevent hyperphosphatemia, reduce dose or.

3. Permanently terminate pemetinib therapy based on the duration and severity of hyperphosphatemia.

4. Embryo-fetal toxicity: Pemetinib can cause fetal harm. Inform patients of the potential risk to the fetus of reproductive potential and to use effective contraception.

Mechanism of action:

1. Pemetinib is a small molecule kinase inhibitor targeting FGFR1, 2 and 3, with an IC50 value of less than 2nM.

2. Pemetinib also inhibits FGFR4 in vitro at a concentration that is approximately 100 times higher than that of FGFR1, 2, and 3.

3. Pemetinib leads to constitutive activation of FGFR by activating FGFR amplification and fusion, thereby inhibiting FGFR1-3 phosphorylation and signaling and reducing cell viability.

4. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Pemetinib demonstrated antitumor activity in mouse xenograft models of human tumors with alterations in FGFR1, FGFR2, or FGFR3, resulting in constitutive FGFR activation, including cholangiocarcinoma xenograft models in patients expressing oncogenic FGFR2-Transformer-2 beta homolog (TRA2b) fusion proteins.

The above is the content of the manual, I hope it can help you!

Recommended related hot articles: /newsDetail/96510.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.